title: Octocog alfa (Advate®): a guide to its use in hemophilia A.
abstract: Prophylaxis or on-demand therapy with octocog alfa, antihemophilic factor, plasma/albumin-free method (Advate(®)) is effective for the prevention and treatment of bleeding episodes and for perioperative management in pediatric and adult patients with hemophilia A. Routine prophylaxis with Advate(®) also prevents bleeding episodes in patients with hemophilia A; moreover, routine prophylaxis with Advate(®) is more effective in preventing bleeding episodes than on-demand therapy. Advate(®) is generally well tolerated in patients with hemophilia A. Serious adverse events with Advate(®) therapy include the development of high-titer factor VIII inhibitors (usually in previously untreated patients) and hypersensitivity reactions. There are no comparative trials of Advate(®) and other factor VIII concentrates. Nevertheless, current evidence indicates that Advate(®) is an effective option for the management of pediatric and adult patients with hemophilia A.
authors: Adis, Auckland, New Zealand. demail@springer.com
authors: Gillian M
authors: GM
authors: Keating
authors: Sohita
authors: S
authors: Dhillon
mesh_terms: D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003029:Coagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005169:Factor VIII / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006470:Hemorrhage / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D003029:Coagulants; D005169:Factor VIII